In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys

References

• Addy C, Cote J, Li S, Agrawal N, Majumdar A, Li H, Yuan J, Dunbar S, Lasseter K, Stoch A, Gottesdiener K, and Wagner J. (2007). Taranabant plasma concentrations increased when co-administered with ketoconazole or diltiazem. Obesity Program Abstract Supplement 15:147–148.
   Google Scholar
• Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN 3rd, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, Depré M, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ, Wagner J, Gottesdiener K, Amatruda JM, Heymsfield SB. (2008). The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68–78.
   PubMed Web of Science ®Google Scholar
• Baillie TA, Davis MR. (1993). Mass spectrometry in the analysis of glutathione conjugates. Biol Mass Spectrom 22:319–325.
   PubMedGoogle Scholar
• Buters JT, Shou M, Hardwick JP, Korzekwa KR, Gonzalez FJ. (1995). cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification. Drug Metab Dispos 23:696–701.
   PubMed Web of Science ®Google Scholar
• Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, Pagotto U. (2003a). Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 27:289–301.
   Google Scholar
• Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U. (2003b). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423–431.
   PubMed Web of Science ®Google Scholar
• Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LH, Goulet MT, Hagmann WK, Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Francis B, Strack AM, MacIntyre DE, Shearman LP. (2007). Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 321:1013–1022.
   PubMed Web of Science ®Google Scholar
• Fretland AJ, Omiecinski CJ. (2000). Epoxide hydrolases: biochemistry and molecular biology. Chem Biol Interact 129:41–59.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2003). Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and related reactions. Arch Biochem Biophys 409:59–71.
   PubMed Web of Science ®Google Scholar
• Hagmann WK. (2008). The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity. Arch Pharm (Weinheim) 341:405–411.
   PubMed Web of Science ®Google Scholar
• Huskey SW, Dean DC, Miller RR, Rasmusson GH, Chiu SH. (1995). Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos 23:1126–1135.
   PubMed Web of Science ®Google Scholar
• Krieter PA, Colletti AE, Doss GA, Miller RR. (1994). Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metab Dispos 22:625–630.
   PubMed Web of Science ®Google Scholar
• Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Fong TM, Shen CP, Lao J, Xiao JC, Shearman LP, Stribling DS, Rosko K, Strack A, Marsh DJ, Feng Y, Kumar S, Samuel K, Yin W, Van der Ploeg LH, Goulet MT, Hagmann WK. (2006). Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 49:7584–7587.
   PubMed Web of Science ®Google Scholar
• Lin LS, Ha S, Ball RG, Tsou NN, Castonguay LA, Doss GA, Fong TM, Shen CP, Xiao JC, Goulet MT, Hagmann WK. (2008). Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist. J Med Chem 51:2108–2114.
   Google Scholar
• Mei Q, Tang C, Assang C, Lin Y, Slaughter D, Rodrigues AD, Baillie TA, Rushmore TH, Shou M. (1999). Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749–759.
   PubMed Web of Science ®Google Scholar
• Murphy CM, Fenselau C, and Gutierrez PL. (1992). Fragmentation characteristics of glutathione conjugates activated by high-energy collisions. J Am Soc Mass Spectrom 3: 815–822.
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. (2000). Central nervous system control of food intake. Nature 404:661–671.
   PubMed Web of Science ®Google Scholar
• Shou M, Dai R, Cui D, Korzekwa KR, Baillie TA, Rushmore TH. (2001). A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem 276:2256–2262.
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389–1397.
   PubMed Web of Science ®Google Scholar